Snakebite is one of the most neglected of all tropical diseases, with nearly 5 million people bitten by snakes each year and fatalities globally up to 30 times higher than that of land mines and comparable to AIDS in some developing countries. It has been estimated that more than 75 percent of snakebite victims who die do so before they ever reach the hospital so a new approach may dramatically reduce the number of global snakebite fatalities, currently estimated to be as high as 94,000 per year.
Such a fast, accessible, and easy-to-administer treatment for venomous snakebite may be coming. Not soon, the regulatory process allows no shortcuts and clinical trials are expensive, but it is in the works.